MCID: ADR040
MIFTS: 40

Adrenal Gland Pheochromocytoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adrenal Gland Pheochromocytoma

MalaCards integrated aliases for Adrenal Gland Pheochromocytoma:

Name: Adrenal Gland Pheochromocytoma 12 15
Pheochromocytoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050892
UMLS 73 C0031511

Summaries for Adrenal Gland Pheochromocytoma

Disease Ontology : 12 An adrenal medulla cancer that is characterized by overproduction of adrenaline.

MalaCards based summary : Adrenal Gland Pheochromocytoma, also known as pheochromocytoma, is related to adrenal carcinoma and pheochromocytoma, and has symptoms including abdominal pain, chest pain and fever. An important gene associated with Adrenal Gland Pheochromocytoma is NOS3 (Nitric Oxide Synthase 3), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Development HGF signaling pathway. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, liver and endothelial, and related phenotypes are cardiovascular system and muscle

Related Diseases for Adrenal Gland Pheochromocytoma

Diseases related to Adrenal Gland Pheochromocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 adrenal carcinoma 11.1
2 pheochromocytoma 10.1
3 hepatopulmonary syndrome 9.7 AKT1 NOS3
4 mitral valve disease 9.6 AKT1 NOS3
5 glucose metabolism disease 9.6 AKT1 NOS3
6 estrogen-receptor positive breast cancer 9.5 AKT1 MTOR
7 arteries, anomalies of 9.5 AKT1 NOS3
8 acquired metabolic disease 9.4 AKT1 NOS3
9 tuberous sclerosis 9.2 AKT1 MTOR
10 diabetes mellitus 8.4 AKT1 MTOR NOS3
11 body mass index quantitative trait locus 11 8.3 AKT1 KCNH2 MTOR NOS3

Graphical network of the top 20 diseases related to Adrenal Gland Pheochromocytoma:



Diseases related to Adrenal Gland Pheochromocytoma

Symptoms & Phenotypes for Adrenal Gland Pheochromocytoma

UMLS symptoms related to Adrenal Gland Pheochromocytoma:


abdominal pain, chest pain, fever, headache, tremor

MGI Mouse Phenotypes related to Adrenal Gland Pheochromocytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.35 AKT1 BNIP3 KCNH2 MTOR NOS3
2 muscle MP:0005369 9.02 AKT1 BNIP3 KCNH2 MTOR NOS3

Drugs & Therapeutics for Adrenal Gland Pheochromocytoma

Drugs for Adrenal Gland Pheochromocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 4,Phase 3,Phase 2 59-96-1 4768
3 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
5 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
6 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
7 Antihypertensive Agents Phase 4,Phase 3,Phase 2
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Vasodilator Agents Phase 4,Phase 3,Phase 2
10
Somatostatin Approved, Investigational Phase 2, Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
11
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
12
Ifosfamide Approved Phase 3 3778-73-2 3690
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
15
Doxil Approved June 1999 Phase 3,Phase 2 31703
16 3-Iodobenzylguanidine Phase 3,Phase 2,Phase 1,Not Applicable
17 Radiopharmaceuticals Phase 3,Phase 2,Phase 1,Not Applicable
18 Hormone Antagonists Phase 2, Phase 3,Phase 1
19 Hormones Phase 2, Phase 3,Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
25
Isophosphamide mustard Phase 3 0
26 Topoisomerase Inhibitors Phase 3,Phase 2
27
Indinavir Approved Phase 2 150378-17-9 5362440
28
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
29
Epinephrine Approved, Vet_approved Phase 2,Not Applicable 51-43-4 5816
30
Racepinephrine Approved Phase 2,Not Applicable 329-65-7 838
31
Carbidopa Approved Phase 2 28860-95-9 34359 38101
32
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
33
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
34
Iodine Approved, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 7553-56-2 807
35
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
36
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
37
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
38
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
39
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
40
Tamoxifen Approved Phase 2 10540-29-1 2733526
41
Melphalan Approved Phase 2 148-82-3 4053 460612
42
Pancrelipase Approved, Investigational Phase 2,Not Applicable 53608-75-6
43
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
44
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
46
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
47
Lenvatinib Approved, Investigational Phase 2 417716-92-8
48
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
49
nivolumab Approved Phase 2 946414-94-4
50
Pembrolizumab Approved Phase 2 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
2 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
3 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
4 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Completed NCT00442533 Phase 2, Phase 3 Indium-111 pentetreotide
8 Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
9 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
10 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
11 131MIBG to Treat Malignant Pheochromocytoma Completed NCT00028106 Phase 2 [131]I-MIBG;6-[18F]Fluorodopamine;[123]I-MIBG
12 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
13 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Completed NCT00843037 Phase 2 Sunitinib
14 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
15 RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Completed NCT01152827 Phase 2 RAD001
16 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2 Fostamatinib disodium
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
20 RAD001 and Erlotinib in Patients With Neuroendocrine Tumors Completed NCT00843531 Phase 2 RAD001;erlotinib
21 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Completed NCT00088374 Phase 2 17 allylamino-17-demethoxygeldanamycin;18 FDG (Fludeoxyglucose 18F);[15-O] H2O;EPL diluent
22 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Recruiting NCT03008369 Phase 2 Lenvatinib
23 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
24 Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib
25 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;Amino Acid solution
26 Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Recruiting NCT00107289 Phase 2
27 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer Recruiting NCT03165721 Phase 2 SGI-110 (guadecitabine)
28 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
29 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
30 MIBG Therapy for Patients With MIBG Avid Tumors Recruiting NCT02378428 Phase 2 MIBG
31 Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2 Pembrolizumab
32 A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
33 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
34 Dovitinib in Neuroendocrine Tumors Active, not recruiting NCT01635907 Phase 2 Dovitinib
35 Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
36 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
37 Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery Withdrawn NCT00770705 Phase 2 Phenoxybenzamine
38 ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
39 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
40 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
41 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
42 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
43 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
44 Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
45 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
46 Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation Unknown status NCT02186678 Not Applicable
47 Evaluation of Plasma Catecholamine Concentration During Surgery Unknown status NCT00948181
48 Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients Unknown status NCT02361996
49 Anesthesia Management of Retroperitoneal Adrenalectomies Unknown status NCT00894335
50 Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma Approved for marketing NCT00730444 Iobenguane I 123 Injection

Search NIH Clinical Center for Adrenal Gland Pheochromocytoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Adrenal Gland Pheochromocytoma

Anatomical Context for Adrenal Gland Pheochromocytoma

MalaCards organs/tissues related to Adrenal Gland Pheochromocytoma:

41
Adrenal Gland, Liver, Endothelial, Thyroid, Lung, Kidney, Testes

Publications for Adrenal Gland Pheochromocytoma

Articles related to Adrenal Gland Pheochromocytoma:

# Title Authors Year
1
Amyloid in adrenal gland pheochromocytomas. ( 7545387 )
1995
2
Radiological seminar CCXLXII: CT of adrenal gland pheochromocytoma. ( 2778800 )
1989

Variations for Adrenal Gland Pheochromocytoma

Cosmic variations for Adrenal Gland Pheochromocytoma:

9
(show top 50) (show all 60)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.593T>C p.L198P 3:10149916-10149916 7
2 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.499C>T p.R167W 3:10149822-10149822 7
3 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.389T>G p.V130G 3:10146562-10146562 7
4 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.491A>G p.Q164R 3:10149814-10149814 7
5 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.492G>T p.Q164H 3:10149815-10149815 7
6 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.482G>A p.R161Q 3:10149805-10149805 7
7 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.227T>A p.F76Y 3:10142074-10142074 7
8 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>A p.V84M 3:10142097-10142097 7
9 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.260T>C p.V87A 3:10142107-10142107 7
10 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.475A>G p.K159E 3:10149798-10149798 7
11 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.496G>T p.V166F 3:10149819-10149819 7
12 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,NS c.250G>C p.V84L 3:10142097-10142097 7
13 COSM10662 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.743G>A p.R248Q 17:7674220-7674220 7
14 COSM44914 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.349G>C p.G117R 17:7676020-7676020 7
15 COSM43678 TP53 adrenal gland,adrenal gland,pheochromocytoma,NS c.305C>T p.T102I 17:7676064-7676064 7
16 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.1900T>C p.C634R 10:43114500-43114500 7
17 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,NS c.2753T>C p.M918T 10:43121968-43121968 7
18 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1885G>A p.Q616fs*4 17:31225134-31225134 7
19 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1721+3A>T p.A548fs*13 17:31221932-31221932 7
20 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7646C>G p.S2549* 17:31356490-31356490 7
21 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.226G>T p.E76* 17:31159031-31159031 7
22 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.5665G>T p.E1889* 17:31330351-31330351 7
23 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1722-1G>A p.? 17:31223443-31223443 7
24 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1466A>G p.Y489C 17:31214524-31214524 7
25 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3158C>A p.S1053* 17:31230886-31230886 7
26 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7582C>T p.Q2528* 17:31352381-31352381 7
27 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.6855C>A p.Y2285* 17:31338739-31338739 7
28 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.4558C>T p.Q1520* 17:31260496-31260496 7
29 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.7300C>T p.Q2434* 17:31349230-31349230 7
30 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.3721C>T p.R1241* 17:31235623-31235623 7
31 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.2409+1G>A p.A776_Q803del 17:31227607-31227607 7
32 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,NS c.205-1G>C p.R69fs*7 17:31159009-31159009 7
33 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.352A>T p.M118L 7:116699436-116699436 7
34 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.3029C>T p.T1010I 7:116771936-116771936 7
35 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,NS c.607T>A p.S203T 7:116699691-116699691 7
36 COSM5945783 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14858A>G p.N4953S 12:49026298-49026298 7
37 COSM144597 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7019T>C p.L2340P 12:49039941-49039941 7
38 COSM5945788 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7954C>T p.R2652W 12:49038592-49038592 7
39 COSM5945782 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.7393G>A p.G2465S 12:49039461-49039461 7
40 COSM5945789 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.14856C>A p.N4952K 12:49026300-49026300 7
41 COSM5945787 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.11854C>G p.L3952V 12:49032041-49032041 7
42 COSM6342201 KMT2D adrenal gland,adrenal gland,pheochromocytoma,NS c.6797T>C p.F2266S 12:49040163-49040163 7
43 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.182A>G p.Q61R 11:533874-533874 7
44 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.181C>A p.Q61K 11:533875-533875 7
45 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,NS c.37G>C p.G13R 11:534286-534286 7
46 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,NS c.103G>T p.G35W 1:226064454-226064454 7
47 COSM27887 GNAS adrenal gland,adrenal gland,pheochromocytoma,NS c.601C>T p.R201C 20:58909365-58909365 7
48 COSM19176 FGFR1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1638C>A p.N546K 8:38417331-38417331 7
49 COSM6188660 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1592C>T p.P531L 2:46380264-46380264 7
50 COSM6196778 EPAS1 adrenal gland,adrenal gland,pheochromocytoma,NS c.1104G>A p.M368I 2:46376608-46376608 7

Expression for Adrenal Gland Pheochromocytoma

Search GEO for disease gene expression data for Adrenal Gland Pheochromocytoma.

Pathways for Adrenal Gland Pheochromocytoma

Pathways related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 AKT1 MTOR NOS3
2
Show member pathways
12.42 AKT1 MTOR NOS3
3
Show member pathways
12.18 AKT1 MTOR NOS3
4
Show member pathways
12.12 AKT1 MTOR NOS3
5
Show member pathways
11.87 AKT1 MTOR NOS3
6
Show member pathways
11.84 AKT1 MTOR NOS3
7 11.79 AKT1 MTOR NOS3
8 11.71 AKT1 MTOR
9
Show member pathways
11.7 AKT1 MTOR
10 11.69 AKT1 NOS3
11 11.68 AKT1 MTOR
12
Show member pathways
11.68 AKT1 MTOR
13 11.68 AKT1 MTOR NOS3
14 11.66 AKT1 NOS3
15 11.65 AKT1 NOS3
16
Show member pathways
11.65 AKT1 NOS3
17
Show member pathways
11.61 AKT1 MTOR
18 11.61 AKT1 MTOR
19 11.6 AKT1 BNIP3 MTOR
20
Show member pathways
11.59 AKT1 NOS3
21
Show member pathways
11.56 AKT1 NOS3
22 11.55 AKT1 MTOR
23
Show member pathways
11.53 AKT1 MTOR
24 11.53 AKT1 MTOR
25 11.5 AKT1 MTOR
26 11.49 AKT1 MTOR
27
Show member pathways
11.48 AKT1 MTOR
28 11.47 AKT1 NOS3
29
Show member pathways
11.47 AKT1 MTOR NOS3
30 11.46 AKT1 MTOR
31 11.45 AKT1 MTOR
32 11.45 AKT1 BNIP3
33 11.43 AKT1 MTOR
34 11.42 AKT1 MTOR
35 11.34 AKT1 MTOR
36 11.33 AKT1 MTOR NOS3
37 11.27 AKT1 MTOR
38 11.24 AKT1 NOS3
39 11.12 AKT1 MTOR
40 11.11 AKT1 MTOR
41 11.06 AKT1 MTOR
42 11.03 AKT1 MTOR
43 10.97 AKT1 MTOR
44 10.93 AKT1 NOS3
45 10.92 AKT1 BNIP3 MTOR
46 10.87 AKT1 NOS3
47 10.73 AKT1 MTOR
48 10.28 AKT1 MTOR NOS3

GO Terms for Adrenal Gland Pheochromocytoma

Biological processes related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cellular response to mechanical stimulus GO:0071260 9.64 AKT1 BNIP3
2 peptidyl-threonine phosphorylation GO:0018107 9.63 AKT1 MTOR
3 positive regulation of endothelial cell proliferation GO:0001938 9.63 AKT1 MTOR
4 response to hormone GO:0009725 9.62 AKT1 NOS3
5 positive regulation of smooth muscle cell proliferation GO:0048661 9.62 AKT1 MTOR
6 negative regulation of protein ubiquitination GO:0031397 9.61 AKT1 MTOR
7 protein catabolic process GO:0030163 9.61 AKT1 MTOR
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.6 AKT1 NOS3
9 response to heat GO:0009408 9.59 AKT1 NOS3
10 cardiac muscle contraction GO:0060048 9.58 KCNH2 MTOR
11 negative regulation of autophagy GO:0010507 9.58 AKT1 MTOR
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.57 AKT1 MTOR
13 germ cell development GO:0007281 9.56 AKT1 MTOR
14 activation of protein kinase B activity GO:0032148 9.55 AKT1 MTOR
15 spinal cord development GO:0021510 9.54 AKT1 MTOR
16 lipopolysaccharide-mediated signaling pathway GO:0031663 9.52 AKT1 NOS3
17 regulation of nitric-oxide synthase activity GO:0050999 9.51 AKT1 NOS3
18 TOR signaling GO:0031929 9.49 AKT1 MTOR
19 regulation of myelination GO:0031641 9.48 AKT1 MTOR
20 positive regulation of lipid biosynthetic process GO:0046889 9.46 AKT1 MTOR
21 negative regulation of macroautophagy GO:0016242 9.43 AKT1 MTOR
22 nitric oxide biosynthetic process GO:0006809 9.4 AKT1 NOS3
23 cofactor metabolic process GO:0051186 9.37 AKT1 NOS3
24 anoikis GO:0043276 9.32 AKT1 MTOR
25 negative regulation of cell size GO:0045792 9.26 AKT1 MTOR
26 response to fluid shear stress GO:0034405 9.16 AKT1 NOS3
27 cellular response to hypoxia GO:0071456 9.13 AKT1 BNIP3 MTOR
28 regulation of glycogen biosynthetic process GO:0005979 8.62 AKT1 MTOR

Molecular functions related to Adrenal Gland Pheochromocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 scaffold protein binding GO:0097110 8.96 KCNH2 NOS3
2 identical protein binding GO:0042802 8.92 AKT1 BNIP3 KCNH2 MTOR

Sources for Adrenal Gland Pheochromocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....